Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMSO-Based Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Vaccine Injury
NCT07567274Phase 2Enrolling by invitation
- Sponsor
- Leading Edge Clinic
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Dimethyl sulfoxide in tinnitus, sponsored by Leading Edge Clinic. Started May 2026; status: enrolling by invitation.
02
Drugs
Dimethyl sulfoxide
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT07567274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567274.